• Explore /
  • Poster
  • / Phase II study of alisertib, irinotecan, and temozolomide in children with relapsed and refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.

Phase II study of alisertib, irinotecan, and temozolomide in children with relapsed and refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.

Abstract Poster

Authors

null

Steven G. DuBois

Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA

Steven G. DuBois , Araz Marachelian , Elizabeth Fox , Rachel A. Kudgus , Joel M. Reid , Susan G. Groshen , Jemily Malvar , Rochelle Bagatell , Lars M. Wagner , John M. Maris , Randall Hawkins , Jesse Courtier , Hollie Lai , Fariba Goodarzian , Hiroyuki Shimada , Najee Boucher , Scarlett Czarnecki , Denice D Tsao-Wei , Katherine K. Matthay , Yael P. Mosse

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Pediatric Oncology

Track

Pediatric Oncology

Sub Track

Pediatric Solid Tumors

Clinical Trial Registration Number

NCT01601535

Citation

J Clin Oncol 34, 2016 (suppl; abstr 10556)

DOI

10.1200/JCO.2016.34.15_suppl.10556

Abstract #

10556

Poster Bd #

247

Abstract Disclosures

Similar Posters

First Author: Shakeel Modak

First Author: Godfrey Chi-Fung Chan

First Author: Jaume Mora

First Author: Steven G. DuBois